Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors alike. ^[1]

Today’s move in PFE is being driven by a cluster of fresh catalysts:

• A new obesity-pill partnership with China’s YaoPharma that could be worth up to $2.1 billion
• Phase 3 wins in oncology and hemophilia, including major updates for TUKYSA (tucatinib) and HYMPAVZI (marstacimab) ^[2]
• A new round of job cuts in Switzerland as part of a multi‑year cost‑saving plan
• Ongoing debate on valuation, dividend safety and long‑term growth across Wall Street and financial media

Below is a detailed, news‑driven look at Pfizer stock today — including the latest news, forecasts and analysis relevant to 10 December 2025.

1. PFE Stock Snapshot on 10 December 2025

• Recent price: about $25.5 per share in U.S. trading, up less than 1% intraday ^[3]
• Market cap: roughly in the mid‑$140 billion range at this price point ^[4]
• Dividend yield: around 6.6–6.8%, based on an annual dividend of $1.72 per share ^[5]
• Forward earnings guidance (Pfizer): 2025 adjusted EPS of $3.00–$3.15, reaffirmed and raised with Q3 results ^[6]

On a forward P/E basis, multiple independent analyses still see Pfizer trading at roughly 8x 2025 earnings, well below both the broader market and many large pharma peers. ^[7]

Despite this, PFE is down more than 50% from its December 2021 all‑time high, reflecting the collapse of COVID‑era revenues and lingering skepticism about its post‑pandemic growth story. ^[8]

2. New Obesity Drug Deal: Pfizer Bets Again on GLP‑1

One of the biggest storylines around Pfizer stock this week is its new obesity‑drug partnership with YaoPharma, a unit of China’s Shanghai Fosun Pharmaceutical.

Key deal terms

According to Pfizer’s 9 December 2025 press release: ^[9]

• Pfizer is in‑licensing YP05002, an oral small‑molecule GLP‑1 receptor agonist currently in Phase 1 for chronic weight management.
• YaoPharma completes the ongoing Phase 1 trial, then Pfizer takes over global development, manufacturing and commercialization.
• YaoPharma receives:
  • $150 million upfront cash, plus
  • Up to $1.935 billion in development, regulatory and commercial milestones,
  • Plus tiered royalties on future sales if the drug is approved.

Pfizer plans to test YP05002 in combination with its own GIPR antagonist PF‑07976016 (Phase 2) and other metabolic candidates, aiming for differentiated obesity regimens rather than a single stand‑alone pill. ^[10]

Why it matters for PFE stock

• The global obesity market is projected to surpass $100 billion by 2030, dominated today by injectable GLP‑1 drugs from Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). ^[11]
• Pfizer’s earlier attempts — including danuglipron, a prior oral GLP‑1 that was scrapped over liver‑toxicity concerns — left investors doubting its ability to compete. ^[12]
• The Metsera acquisition (≈$10 billion) in November and this YaoPharma deal now mark a reset of Pfizer’s obesity strategy, with a pipeline of multiple incretin and amylin assets rather than a single “make‑or‑break” pill. ^[13]

Analysts at Zacks argue that Pfizer’s valuation screens as attractive relative to peers precisely because the market is not fully pricing in the upside from this renewed obesity push. ^[14]

From a stock perspective, the GLP‑1 partnership is an option on a massive future market: it’s early‑stage and risky, but if efficacy and safety data cooperate, it could materially change Pfizer’s growth profile in the second half of the decade.

3. Oncology Tailwind: TUKYSA’s Phase 3 Win in HER2+ Breast Cancer

Another major catalyst driving sentiment today is positive Phase 3 data for TUKYSA® (tucatinib) in metastatic HER2‑positive breast cancer.

HER2CLIMB‑05 results

Pfizer’s 10 December press release on the HER2CLIMB‑05 trial reported: ^[15]

• Adding TUKYSA + trastuzumab + pertuzumab as first‑line maintenance therapy after induction chemotherapy:
  • Reduced the risk of disease progression or death by 35.9% vs. standard trastuzumab + pertuzumab alone (HR 0.641, p < 0.0001).
  • Extended median progression‑free survival (PFS) by 8.6 months:
    • 24.9 months in the TUKYSA arm vs. 16.3 months in the control arm.
• The PFS benefit held across key patient subgroups, including those with or without brain metastases.
• Safety profile was broadly consistent with known TUKYSA and anti‑HER2 toxicities, with a higher—but manageable—rate of liver enzyme elevations.

TUKYSA is already a standard of care in later‑line HER2+ metastatic breast cancer; these results support a potential move earlier in the treatment algorithm, which could materially expand its commercial opportunity. ^[16]

BMO’s Outperform rating and $30 target

Off the back of this data, BMO Capital today reiterated an Outperform rating on Pfizer with a $30 share‑price target, explicitly highlighting tucatinib as a key driver of value in Pfizer’s Seagen‑acquired oncology portfolio. ^[17]

BMO notes:

• TUKYSA’s data support first‑line, maintenance‑regimen use in HER2+ metastatic breast cancer.
• Pfizer currently offers a dividend yield of ~6.8% and trades at a P/E of roughly 14–15x on one commonly used metric, while still screening as undervalued relative to their fair‑value models. ^[18]

For investors, this reinforces the oncology pillar of Pfizer’s story and supports the argument that the Seagen acquisition is beginning to pay off in concrete trial wins rather than just pipeline slides.

4. Hemophilia Breakthrough: HYMPAVZI Slashes Bleeding by 93%

On top of oncology progress, Pfizer has also released strong data in hemophilia, another high‑value specialty franchise.

BASIS Phase 3 highlights

Results from the BASIS Phase 3 trial for HYMPAVZI® (marstacimab) in adults and adolescents with hemophilia A or B with inhibitors show: ^[19]

• 93% reduction in mean treated annualized bleeding rate (ABR) vs. prior on‑demand bypassing therapy (1.39 vs. 19.78).
• Superiority across key bleeding endpoints: spontaneous bleeds, joint bleeds, target joint bleeds, and total treated + untreated bleeds.
• Once‑weekly subcutaneous injection with minimal preparation and no routine lab monitoring, addressing a major burden versus traditional factor infusions.
• Improvements in multiple quality‑of‑life scores, including physical health and overall health‑related QoL.

HYMPAVZI is already approved in 40+ countries for certain hemophilia patients without inhibitors, and Pfizer has now submitted the new inhibitor data to the U.S. FDA and EMA for review. ^[20]

If regulators grant label expansions, HYMPAVZI could become a cornerstone prophylactic therapy for a subset of patients with particularly complex and costly disease, strengthening Pfizer’s rare‑disease franchise and adding visibility to long‑duration revenues.

5. Cost‑Cutting and Layoffs: Swiss Job Cuts and AI‑Driven Efficiency

Pfizer’s fundamental turnaround is not only about new drugs; it is also being driven by aggressive cost‑cutting.

Swiss layoffs make headlines

Today Reuters reported that Pfizer will cut more than 200 jobs in Switzerland, reducing its Swiss workforce from about 300 employees to roughly 70 by year‑end, as part of its multi‑year cost‑reduction program. ^[21]

The move feeds into a broader plan to deliver around $7–7.7 billion in net cost savings by 2027, as management pivots away from volatile COVID revenues to a more sustainable operating base. ^[22]

AI‑enhanced savings

A deeper look at recent analysis shows that Pfizer is leaning heavily on AI and automation to unlock those savings:

• By December 2025, independent commentary estimates Pfizer is targeting over $7 billion in annual cost savings by 2027, with AI‑driven efficiencies a key plank of the plan. ^[23]
• Q3 2025 results show SI&A and R&D expenses both declining year‑over‑year, even as non‑COVID revenue grows modestly, indicating some of those efficiency gains are already feeding through to margins. ^[24]

For the stock, cost‑cutting does double duty: it supports EPS, helping justify the dividend, but also raises execution and morale risks as Pfizer restructures across multiple geographies.

6. Fundamentals Check: Q3 2025 Results and Guidance

Pfizer’s Q3 2025 earnings, reported on 4 November, provide the backdrop for today’s news flow. Key numbers: ^[25]

• Revenue: $16.7 billion (down 6% year‑over‑year; 7% decline on an operational basis)
• Non‑COVID portfolio: up 4% operationally, offsetting a steep drop in Paxlovid and Comirnaty sales
• Adjusted diluted EPS:$0.87, a solid beat versus many Street expectations
• 2025 revenue guidance: reaffirmed at $61–64 billion
• 2025 adjusted EPS guidance:raised and narrowed from $2.90–$3.10 to $3.00–$3.15

Management also reiterated that it is on track to deliver about $7.2 billion in net cost savings by end‑2027, with a view to expanding operating margins despite flat to slightly declining top‑line revenue over the next two years. ^[26]

Taken together, these figures suggest a company that has successfully stabilized post‑COVID earnings, even if it has not yet re‑entered a strong growth phase.

7. How Wall Street Sees Pfizer Now: Ratings and Price Targets

Consensus: “Hold,” moderate upside

Across multiple data providers, the consensus view on PFE remains “Hold”, with modest double‑digit upside over the next 12 months:

• MarketBeat:
  • Consensus rating: Hold from 19 analysts (1 Sell, 12 Hold, 6 Buy / Strong Buy).
  • Average 12‑month price target:$28.56, implying ~11.7% upside from around $25.6. ^[27]
• ValueInvesting.io:
  • 33‑analyst consensus: Hold.
  • Average target:$29.69 (range $24.24–$39.42), implying ~15% upside. ^[28]
• StockAnalysis.com:
  • Similar “Hold” consensus with an average target near $28.3, about 10–11% upside, and 2025 EPS forecast around $3.17. ^[29]

Independent long‑form analysis from 24/7 Wall St. goes further, projecting PFE at $33.60 by end‑2025 (≈31% upside) and $34.08 by 2030, assuming successful cost‑cutting and execution of its non‑COVID pipeline. ^[30]

Selected recent analyst moves

Recent rating and target updates include: ^[31]

• BMO Capital: Outperform, target $30 (reiterated 10 December 2025; oncology strength)
• Guggenheim: Strong Buy, target raised to $35 (late November 2025; bullish on Metsera obesity assets)
• Bank of America: Hold, target raised to $30 (October 2025)
• Citigroup: Hold, initiated/maintained at $26 (latest move 2 December 2025)
• Zacks:Rank #3 (Hold) with earnings estimates for 2025 nudging up to around $3.14 per share. ^[32]

Overlay these with opinion pieces arguing that Pfizer has “one of the most powerful drug pipelines in pharma” and remains deeply discounted versus historical multiples, and you get a picture of cautious optimism rather than broad bullishness. ^[33]

8. What the Commentators Are Saying Today

Financial media and analyst‑style blogs have been particularly busy on Pfizer this week:

• Why PFE is up today: MarketBeat’s AI‑generated recap attributes today’s bounce to the YaoPharma obesity deal, strong TUKYSA data, and the Swiss cost‑cut announcement, with downside risks from ongoing vaccine‑safety headlines and tough comparisons to peers like J&J. ^[34]
• Dividend and valuation debate: Recent pieces at CoinCentral and Parameter highlight a ~6.6% yield, 347 consecutive dividends, and a forward P/E near 8–9x, asking whether investors are over‑penalizing Pfizer for its COVID comedown and upcoming patent cliff. ^[35]
• AI‑driven cost savings: Parameter’s December 8 article frames Pfizer as a high‑yield, AI‑efficiency story, with non‑COVID medicines now driving the majority of revenue and Q3 guidance upgrades backing management’s cost‑cutting narrative. ^[36]
• “Down 50% — buy the dip?”: Several outlets, including Motley Fool and 24/7 Wall St., stress that while the stock has been a “bitter pill” for holders, the combination of pipeline progress and low valuation could set up multi‑year rebound potential if execution stays on track. ^[37]

Overall tone: mixed but improving. The market is starting to reward concrete wins (like TUKYSA and HYMPAVZI data) and obesity optionality, but skepticism remains entrenched.

9. Key Risks and Headwinds for PFE Investors

Despite the good news, several real risks keep many analysts in the “Hold” camp:

1. Patent cliff (2026–2027)
   Major products face upcoming generic and biosimilar competition, pressuring revenue unless newer launches ramp quickly enough. ^[38]
2. Competition in obesity and oncology
   • Obesity drugs are currently dominated by Lilly and Novo Nordisk, who are already advancing their own oral GLP‑1s. ^[39]
   • In oncology, Pfizer’s Seagen assets compete in crowded indications with multiple strong incumbents.
3. Regulatory and safety overhang
   • Ongoing FDA scrutiny in RSV‑related products, even if not specific to Pfizer, adds volatility around its Abrysvo vaccine franchise. ^[40]
   • Various COVID‑vaccine‑related allegations and litigation continue to generate headline risk, even if the fundamental impact remains uncertain. ^[41]
4. Flat top‑line growth near term
   Consensus forecasts see 2025 and 2026 revenue essentially flat or slightly down, even as EPS recovers, suggesting the story is margin‑driven rather than revenue‑driven in the near term. ^[42]
5. Restructuring execution risk
   Multi‑year workforce reductions and portfolio shifts can introduce operational risk, culture challenges, and, in some cases, regulatory or political backlash. ^[43]

Investors must weigh these against the upside from the pipeline, cost programs and valuation.

10. Bull Case vs. Bear Case for Pfizer Stock (December 2025)

The Bull Case

• High, seemingly sustainable dividend around 6.5–7%, supported by rising non‑COVID EPS and big cost savings. ^[44]
• Pipeline momentum, with:
  • TUKYSA’s Phase 3 HER2CLIMB‑05 success
  • HYMPAVZI’s 93% bleed reduction in inhibitor patients
  • A broadened obesity pipeline via Metsera and YaoPharma. ^[45]
• Valuation discount vs. peers: many models put fair value several dollars above today’s price, with consensus targets in the high‑$20s and independent forecasts stretching into the low‑$30s. ^[46]
• Shift beyond COVID: Non‑COVID drugs now drive most revenue, reducing earnings volatility and re‑anchoring the business in more durable franchises like oncology, cardiometabolic disease and rare conditions. ^[47]

The Bear Case

• Growth skepticism: Forecasts still show flat top‑line and only modest EPS growth after the 2025 reset, with big questions about whether the pipeline can fully replace the lost COVID windfall and offset patent expiries. ^[48]
• Crowded competitive fields in obesity and oncology, where Pfizer is now more of a challenger than a first mover. ^[49]
• Headline and legal risk from vaccine‑related controversies and regulatory reviews that could periodically hit sentiment, even if ultimate liabilities are manageable. ^[50]
• Restructuring fatigue: Continued layoffs and site rationalizations may deliver savings but can also erode organizational stability and innovation capacity if not managed carefully. ^[51]

11. What to Watch Next for PFE

Looking beyond today’s session, several upcoming events and milestones could move Pfizer stock:

1. December 16, 2025 analyst call
   Pfizer has invited investors to a webcast on 16 December, where it will provide full‑year 2026 guidance. This will be crucial for understanding how management sees growth, margins and capital allocation post‑COVID and post‑Metsera. ^[52]
2. Regulatory decisions
   • Potential label expansion for TUKYSA based on HER2CLIMB‑05. ^[53]
   • HYMPAVZI submissions to FDA and EMA for inhibitor patients. ^[54]
3. Obesity pipeline updates
   Data flow from YP05002 Phase 1, combination trials with PF‑07976016, and progress across the Metsera incretin/amylin programs will help the market gauge whether Pfizer can carve out a meaningful share of the obesity mega‑market. ^[55]
4. Further cost‑cutting announcements
   Additional restructuring news — positive or negative — may continue to drive EPS revisions and sentiment as investors watch whether Pfizer can hit its multi‑billion‑dollar savings target. ^[56]

12. Bottom Line: How Does Pfizer Stock Look on 10 December 2025?

On 10 December 2025, Pfizer is not trading like a high‑growth biotech — it’s trading like a high‑yield value stock with meaningful but unproven upside:

• The dividend is rich and, based on current guidance and cost savings, appears reasonably well‑covered, though not risk‑free.
• The pipeline is starting to produce tangible wins in oncology and hemophilia, and management is making a serious second attempt at obesity drugs.
• Wall Street remains cautious, but consensus targets still imply 10–15% price upside from today’s levels, with more optimistic forecasts pointing to 30%+ potential if execution goes well. ^[57]

For income‑oriented investors comfortable with pharma‑specific risks, PFE looks like a classic high‑yield, moderate‑upside value play. More growth‑focused investors may prefer to wait for clearer evidence that the obesity and oncology bets are translating into sustained revenue acceleration, not just one‑off trial headlines.

References

1. coincentral.com, 2. www.businesswire.com, 3. www.marketbeat.com, 4. parameter.io, 5. parameter.io, 6. www.businesswire.com, 7. www.nasdaq.com, 8. 247wallst.com, 9. www.businesswire.com, 10. www.businesswire.com, 11. www.nasdaq.com, 12. www.nasdaq.com, 13. www.nasdaq.com, 14. www.nasdaq.com, 15. www.businesswire.com, 16. www.businesswire.com, 17. www.investing.com, 18. www.investing.com, 19. www.businesswire.com, 20. www.businesswire.com, 21. www.reuters.com, 22. www.reuters.com, 23. parameter.io, 24. www.businesswire.com, 25. www.businesswire.com, 26. www.businesswire.com, 27. www.marketbeat.com, 28. valueinvesting.io, 29. stockanalysis.com, 30. 247wallst.com, 31. stockanalysis.com, 32. www.nasdaq.com, 33. seekingalpha.com, 34. www.marketbeat.com, 35. coincentral.com, 36. parameter.io, 37. www.marketbeat.com, 38. parameter.io, 39. www.nasdaq.com, 40. parameter.io, 41. www.marketbeat.com, 42. stockanalysis.com, 43. www.reuters.com, 44. parameter.io, 45. www.businesswire.com, 46. www.marketbeat.com, 47. www.businesswire.com, 48. stockanalysis.com, 49. www.nasdaq.com, 50. www.marketbeat.com, 51. www.reuters.com, 52. www.businesswire.com, 53. www.businesswire.com, 54. www.businesswire.com, 55. www.nasdaq.com, 56. www.reuters.com, 57. www.marketbeat.com